Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-2006-925029 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Use of endoscopic submucosal dissection or full-thickness resection device to treat residual colorectal neoplasia after endoscopic resection: a multicenter historical cohort study.
Endoscopy
November 2023
Endoscopy and Gastroenterology Unit, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.
INTRODUCTION : Residual colorectal neoplasia (RCN) after previous endoscopic mucosal resection is a frequent challenge. Different management techniques are feasible including endoscopic full-thickness resection using the full-thickness resection device (FTRD) system and endoscopic submucosal dissection (ESD). We aimed to compare the efficacy and safety of these two techniques for the treatment of such lesions.
View Article and Find Full Text PDFEfficacy and safety of colesevelam for the treatment of bile acid diarrhoea: a double-blind, randomised, placebo-controlled, phase 4 clinical trial.
Lancet Gastroenterol Hepatol
April 2023
Zealand University Hospital, Department of Internal Medicine, Køge, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Background: Bile acid diarrhoea is a common but overlooked cause of chronic watery diarrhoea. Plasma 7α-hydroxy-4-cholesten-3-one (C4) is an alternative to the gold standard tauroselcholic [Se] acid (SeHCAT) test. Low-certainty evidence supports sequestrant treatment, including colesevelam.
View Article and Find Full Text PDFSelecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD.
Gastroenterology
April 2021
Department of Gastroenterology and INSERM NGERE U1256, Nancy University Hospital, University of Lorraine, Vandœuvre-lès-Nancy, France. Electronic address:
Background And Aims: Inflammatory bowel diseases (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), are chronic and disabling disorders. Prospective disease-modification trials to prevent disease progression are eagerly awaited. However, disease progression is not clearly defined.
View Article and Find Full Text PDFUnited European Gastroenterology Week (UEGW) 2017 - 25th Annual Conference (October 28-November 1, 2017 - Barcelona, Spain).
Drugs Today (Barc)
November 2017
Clarivate Analytics, Barcelona, Spain.
The 25th United European Gastroenterology Week (UEGW), the largest European conference centered on diseases of the stomach, bowel, esophagus, liver, pancreas and gallbladder, was held in Barcelona, Spain. This 5-day meeting attracted over 13,000 delegates to share recent research in the treatment of gastrointestinal and liver diseases. The conference provided teaching material, workshops and live sessions to all the attendants.
View Article and Find Full Text PDFUnited European Gastroenterology Week scientific abstracts and their progression to full publication.
Eur J Gastroenterol Hepatol
October 2017
aDepartment of Gastroenterology, Royal Hallamshire Hospital bAcademic Unit of Gastroenterology, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.
Objective: Abstracts presentations at scientific meetings enable rapid dissemination of novel research. The percentage of abstracts that proceed to full publication from differing medical specialties is highly variable. This study aims to evaluate the outcomes of abstracts presented at the United European Gastroenterology Week (UEGW).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!